Chordia Therapeutics Inc. (JP:190A)
:190A
Top Page
Chordia Therapeutics Inc.
(190A)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥128.00
▲(18.52% Upside)
Action:ReiteratedDate:03/04/26
The score is held down primarily by weak financial performance (zero recent revenue, large losses, and significant cash burn with declining equity). Technical indicators provide some offset with improving short- to mid-term momentum, while valuation remains constrained by ongoing losses and no dividend yield data.
Positive Factors
Low leverage / no debt
The absence of reported debt materially lowers financial fragility and interest burden, giving management flexibility to fund R&D, pursue partnerships, or raise capital on better terms. For a development-stage biotech this durable low-leverage profile extends runway options during multi-year clinical development.
Negative Factors
Sustained cash burn
Large negative operating and free cash flows across consecutive years indicate sustained cash burn that materially shortens runway absent new funding. Over the medium term this raises the likelihood of dilutive equity raises or restrictive financing, constraining long-term R&D investment and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
The absence of reported debt materially lowers financial fragility and interest burden, giving management flexibility to fund R&D, pursue partnerships, or raise capital on better terms. For a development-stage biotech this durable low-leverage profile extends runway options during multi-year clinical development.
Read all positive factors
Chordia Therapeutics Inc. (190A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.18B
Dividend YieldN/A
Average Volume (3M)565.44K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,167,900
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chordia Therapeutics Inc. Business Overview & Revenue Model
Company Description
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporat...
How the Company Makes Money
Chordia Therapeutics Inc. primarily generates revenue through the development and commercialization of its proprietary drug candidates. The company earns income from licensing agreements, milestone payments, and royalties from partnerships with la...
Chordia Therapeutics Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 2.50B | 0.00 | 800.00M |
| Gross Profit | -1.43B | -4.09M | 0.00 | -3.15M | 0.00 |
| EBITDA | -1.79B | -1.82B | 218.10M | -1.77B | -586.97M |
| Net Income | -1.79B | -1.83B | 223.34M | -1.78B | -527.11M |
Balance Sheet | |||||
| Total Assets | 2.68B | 4.63B | 4.91B | 4.50B | 2.27B |
| Cash, Cash Equivalents and Short-Term Investments | 2.55B | 4.33B | 4.80B | 4.25B | 2.00B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 244.34M | 471.07M | 408.24M | 221.41M | 214.95M |
| Stockholders Equity | 2.44B | 4.16B | 4.50B | 4.28B | 2.06B |
Cash Flow | |||||
| Free Cash Flow | -1.84B | -1.94B | 543.01M | -1.72B | -546.92M |
| Operating Cash Flow | -1.84B | -1.94B | 543.73M | -1.70B | -544.59M |
| Investing Cash Flow | -5.33M | -10.96M | 345.00K | -14.70M | -2.36M |
| Financing Cash Flow | 61.58M | 1.48B | 0.00 | 3.98B | 1.53B |
Chordia Therapeutics Inc. Technical Analysis
Positive
108.00
Price Trends
125.22
Positive
117.85
Positive
142.39
Negative
Market Momentum
0.73
Positive
51.91
Neutral
43.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Positive. The current price of 108 is below the 20-day moving average (MA) of 126.90, below the 50-day MA of 125.22, and below the 200-day MA of 142.39, indicating a neutral trend. The MACD of 0.73 indicates Positive momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 43.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:190A.
Chordia Therapeutics Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥7.87B | -11.77 | ― | ― | -12.40% | 43.42% | |
64 Neutral | ¥45.03B | 10.10 | ― | 2.53% | 2.74% | -7.19% | |
63 Neutral | ¥43.96B | 239.59 | ― | ― | ― | ― | |
60 Neutral | ¥524.40B | 22.79 | ― | 0.93% | 3.73% | 18.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥6.12B | -12.09 | ― | 2.65% | 15.66% | 56.93% | |
47 Neutral | ¥9.18B | -6.49 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:190A
Chordia Therapeutics Inc.
129.00
-121.00
-48.40%
JP:2796
Pharmarise Holdings Corp.
521.00
58.52
12.65%
JP:3349
COSMOS Pharmaceutical Corporation
6,588.00
-1,475.88
-18.30%
JP:4890
Tsubota Laboratory Incorporated
305.00
-57.00
-15.75%
JP:4931
Shinnihonseiyaku Co., Ltd.
2,104.00
-140.62
-6.26%
JP:219A
Heartseed, Inc.
1,923.00
-434.00
-18.41%
Chordia Therapeutics Inc. Corporate Events
Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort
Mar 18, 2026
Chordia Therapeutics Inc. has begun dosing the first patient in the Initial Expansion Cohort of its ongoing Phase 1/2 U.S. clinical trial of rogocekib, following a recommendation from the study’s Safety Review Committee. The transition to th...
Chordia Advances Rogocekib Leukemia Trial With FDA-Aligned Expansion Cohorts
Feb 26, 2026
Chordia Therapeutics Inc., a Japan-based oncology-focused biopharmaceutical developer, is advancing its pipeline of targeted cancer therapies led by rogocekib (CLK inhibitor CTX-712) in a Phase 1/2 U.S. trial. The company is also researching addit...
Chordia Regains Full Rights to CTX-177 After Ending Ono License Deal
Feb 18, 2026
Chordia Therapeutics has formally terminated its license agreement with Ono Pharmaceutical for CTX-177, a MALT1 inhibitor for lymphoid hematologic cancers, following Ono’s earlier strategic decision to halt development and return global righ...
Chordia Therapeutics’ Major Shareholder Diluted Below 10% After Warrant Exercises
Feb 3, 2026
Chordia Therapeutics has announced a change in its major shareholder structure after the exercise of its 9th Series Stock Acquisition Rights and other stock acquisition rights increased the total number of voting rights outstanding. As a result, t...
Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink
Jan 14, 2026
Chordia Therapeutics reported non-consolidated results for the quarter ended 30 November 2025 showing no business revenue and a narrowed operating loss of ¥306 million, improving from a ¥624 million loss a year earlier, with quarterly ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.